[The cost effectiveness of adalimumab in Crohn's disease (review of foreign pharmacoeconomic studies)].
A V
AV
Rudakova
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003424:Crohn Disease / Q000188:drug therapy* / Q000191:economics*; D006801:Humans
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab